Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes
- Roswell Park Cancer Institute, United States
- University of Maryland, Baltimore County, United States
- University of Minnesota, United States
- University of Wisconsin-Milwaukee, United States
Abstract
Myeloid-derived suppressor cells (MDSC) contribute to an immunosuppressive network that drives cancer escape by disabling T cell adaptive immunity. The prevailing view is that MDSC-mediated immunosuppression is restricted to tissues where MDSC co-mingle with T cells. Here we show that splenic or, unexpectedly, blood-borne MDSC execute far-reaching immune suppression by reducing expression of the L-selectin lymph node (LN) homing receptor on naïve T and B cells. MDSC-induced L-selectin loss occurs through a contact-dependent, post-transcriptional mechanism that is independent of the major L-selectin sheddase, ADAM17, but results in significant elevation of circulating L-selectin in tumor-bearing mice. Even moderate deficits in L-selectin expression disrupt T cell trafficking to distant LN. Furthermore, T cells preconditioned by MDSC have diminished responses to subsequent antigen exposure, which in conjunction with reduced trafficking, severely diminishes antigen-driven expansion in widely-dispersed LN. These results establish novel mechanisms for MDSC-mediated immunosuppression that have unanticipated implications for systemic cancer immunity.
Article and author information
Author details
Funding
National Institutes of Health (CA79765)
- Sharon S Evans
UB Mark Diamond Research Fund
- Amy W Ku
Jennifer Linscott Tietgen Family Foundation
- Joseph J Skitzki
- Sharon S Evans
Breast Cancer Coalition of Rochester
- Scott I Abrams
- Sharon S Evans
NCI Cancer Center Support Grant (5P30 CA016056)
- Kieran O'Loughlin
- Hans Minderman
National Institutes of Health (1R50CA211108)
- Hans Minderman
National Institutes of Health (AI082039)
- Sharon S Evans
National Institutes of Health (T32 CA085183)
- Amy W Ku
National Institutes of Health (5T32 CA108456)
- Colin A Powers
National Institutes of Health (CA203348)
- Bruce Walcheck
National Institutes of Health (GM021248)
- Suzanne Ostrand-Rosenberg
National Institutes of Health (CA115880)
- Suzanne Ostrand-Rosenberg
National Institutes of Health (CA140622)
- Scott I Abrams
National Institutes of Health (CA172105)
- Scott I Abrams
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Ronald N Germain, National Institute of Allergy and Infectious Diseases, United States
Ethics
Animal experimentation: This study was performed in accordance with the recommendations in the NIH Guide for the Care and Use of Laboratory Animals. All of the animals were handled according to approved IACUC protocols at participating institutions (i.e., 859M and 1117M at Roswell Park Cancer Institute; SO01691417 at University of Maryland, Baltimore County; 15-16 #11 at University of Wisconsin, Milwaukee; and 1401-31272A at University of Minnesota). All surgery was performed under appropriate anesthesia and analgesia to minimize suffering and pain. The use of human PBMCs from anonymous, de-identified donors was classified as non-human subject research in accordance with federal regulations and thus not subjected to formal IRB review, but can be accessed through Roswell Park Clinical Research Services under the reference number BDR 069116.
Version history
- Received: April 29, 2016
- Accepted: December 7, 2016
- Accepted Manuscript published: December 8, 2016 (version 1)
- Version of Record published: December 29, 2016 (version 2)
Copyright
© 2016, Ku et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,165
- views
-
- 846
- downloads
-
- 70
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes
eLife 5:e17375.
https://doi.org/10.7554/eLife.17375
Further reading
-
- Cancer Biology
- Cell Biology
Internalization from the cell membrane and endosomal trafficking of receptor tyrosine kinases (RTKs) are important regulators of signaling in normal cells that can frequently be disrupted in cancer. The adrenal tumor pheochromocytoma (PCC) can be caused by activating mutations of the rearranged during transfection (RET) receptor tyrosine kinase, or inactivation of TMEM127, a transmembrane tumor suppressor implicated in trafficking of endosomal cargos. However, the role of aberrant receptor trafficking in PCC is not well understood. Here, we show that loss of TMEM127 causes wildtype RET protein accumulation on the cell surface, where increased receptor density facilitates constitutive ligand-independent activity and downstream signaling, driving cell proliferation. Loss of TMEM127 altered normal cell membrane organization and recruitment and stabilization of membrane protein complexes, impaired assembly, and maturation of clathrin-coated pits, and reduced internalization and degradation of cell surface RET. In addition to RTKs, TMEM127 depletion also promoted surface accumulation of several other transmembrane proteins, suggesting it may cause global defects in surface protein activity and function. Together, our data identify TMEM127 as an important determinant of membrane organization including membrane protein diffusability and protein complex assembly and provide a novel paradigm for oncogenesis in PCC where altered membrane dynamics promotes cell surface accumulation and constitutive activity of growth factor receptors to drive aberrant signaling and promote transformation.
-
- Cancer Biology
- Genetics and Genomics
Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome-edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
